Chemotherapy outcome of patients with choriocarcinoma
- VernacularTitle:Хорионкарцинома өвчний хими эмчилгээний үр дүнг судалсан нь
- Author:
Ariunaa Kh
;
Yanjinsuren D
- Publication Type:Journal Article
- Keywords:
National Cancer Center (NCC);
Etoposide;
Metothrexate;
Actinomycin D;
Cyclophosphamide;
Vincristine (EMA/CO);
Metothrexate Adriamycin;
Cyclophosphamide (MAC);
Human chorionic gonadotropin (HCG)
- From:Mongolian Medical Sciences
2012;159(1):26-30
- CountryMongolia
- Language:Mongolian
-
Abstract:
Background: Choriocarcinoma 15-20 new cases per year diagnosed at National Cancer Center of Mongolia. Due to insufficient necessary new drugs for choriocarcinoma patients, cancer center cannot provide the most useful treatment EMA/CO so patients were treated MAC or metothrexate, Adriamycin and cyclophosphamide. The outcomes of patients with choriocarcinoma treated with combined chemo drugs never been studied in Mongolia.
Goal: To evaluate the results of combined chemotherapy in choriocarcinoma at National Cancer Center of Mongolia.
Methods: Retrospective cohort review of 42 patients with choriocarcinoma who treated with MAC combination chemotherapy at NCC of Mongolia during 2004-2007. Based on MAC ppatients charts we evaluated clinical characteristics, level of HCG during treatment cycles, ultrasound changes and other lab tests.
Results: We treated 42 patients with choriocarcinoma from 2004 through 2007. All patients were treated with MAC combination chemotherapy at NCC. The number of cases with choriocarcinoma is increasing in each year. 37.5% of these patients were aged between 30-34 years old, so it shows maximum incidence occurs during child bearing years. The most common clinical characteristics were 44% bleeding, 32% lower abdominal quadrant pain related to disease stages, 36% cough, and 28% fever. Out of 42 patients 35% of them had lung metastasis which was significantly different than other gynecological cancer metastasis.
Conclusion: MAC combination treatment offers long-term disease-free survival and potential cure in patients with choriocarcinoma. The reported median survival in these group patients is 5 years. Importantly, 56% of patients were lived up to 5 years in remission.
- Full text:P020170422839294310888.pdf
